company background image
GRNA

GreenLight Biosciences Holdings NasdaqGM:GRNA Stock Report

Last Price

US$1.11

Market Cap

US$168.2m

7D

3.7%

1Y

-87.4%

Updated

04 Feb, 2023

Data

Company Financials +

GreenLight Biosciences Holdings

NasdaqGM:GRNA Stock Report

Mkt Cap: US$168.2m

GRNA Stock Overview

GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications.

GRNA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

New

Notes are coming soon

GreenLight Biosciences Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for GreenLight Biosciences Holdings
Historical stock prices
Current Share PriceUS$1.11
52 Week HighUS$15.80
52 Week LowUS$1.00
Beta0
1 Month Change4.72%
3 Month Change-43.37%
1 Year Change-87.37%
3 Year Changen/a
5 Year Changen/a
Change since IPO-88.67%

Recent News & Updates

GreenLight Biosciences cutting 25% of staff as part of realignment

Oct 12

Recent updates

GreenLight Biosciences cutting 25% of staff as part of realignment

Oct 12

GreenLight Biosciences launches $109M in financing

Aug 12

GreenLight Biosciences, Samsung Biologics complete commercial-scale engineering run for mRNA COVID-19 vaccine

Aug 01

GreenLight Biosciences: Synthesizing Cell-Free RNA

Apr 05

Shareholder Returns

GRNAUS BiotechsUS Market
7D3.7%-0.8%1.7%
1Y-87.4%4.4%-9.6%

Return vs Industry: GRNA underperformed the US Biotechs industry which returned 4.5% over the past year.

Return vs Market: GRNA underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is GRNA's price volatile compared to industry and market?
GRNA volatility
GRNA Average Weekly Movement12.3%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: GRNA is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: GRNA's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2008n/aAndrey Zarurhttps://greenlightbiosciences.com

GreenLight Biosciences Holdings, a biotechnology company, manufactures and sells ribonucleic acid (RNA) products for human health and agriculture applications. Its products for human health include mRNA vaccines and therapeutics; and agricultural RNA products to protect honeybees and crops. The company was founded in 2008 and is headquartered in Medford, Massachusetts.

GreenLight Biosciences Holdings Fundamentals Summary

How do GreenLight Biosciences Holdings's earnings and revenue compare to its market cap?
GRNA fundamental statistics
Market CapUS$168.22m
Earnings (TTM)-US$162.96m
Revenue (TTM)US$4.17m

40.3x

P/S Ratio

-1.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GRNA income statement (TTM)
RevenueUS$4.17m
Cost of RevenueUS$128.11m
Gross Profit-US$123.94m
Other ExpensesUS$39.03m
Earnings-US$162.96m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.08
Gross Margin-2,970.69%
Net Profit Margin-3,906.11%
Debt/Equity Ratio34.5%

How did GRNA perform over the long term?

See historical performance and comparison